Guangxin Xia

发表

Potent and novel 11β-HSD1 inhibitors identified from shape and docking based virtual screening.

Bing Xiong, Jingkang Shen, Guangxin Xia, 2011, Bioorganic & medicinal chemistry letters.

Design and Synthesis of (R)‐1‐Arylsulfonylpiperidine‐2‐carboxamides as 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitors

B. Xiong, Jing-kang Shen, Haiyan Liu, 2013, ChemMedChem.

Discovery of 2-Alkyl-1-arylsulfonylprolinamides as 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors.

B. Xiong, Jing-kang Shen, Jianxin Yu, 2012, ACS medicinal chemistry letters.

The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor

Xiaoyan Chen, Zhi-wei Gao, Guangxin Xia, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors.

B. Xiong, Jing-kang Shen, Haiyan Liu, 2013, European journal of medicinal chemistry.

Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.

Q. Wang, Jianxin Yu, W. Xiao, 2019, European journal of medicinal chemistry.

Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.

Jianxin Yu, X. Liao, Guangxin Xia, 2020, European journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.

Wenteng Chen, Jing-kang Shen, Qinjie Weng, 2013, ACS medicinal chemistry letters.

Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeys.

Guangxin Xia, Xin Li, Leduo Zhang, 2019, Regulatory toxicology and pharmacology : RTP.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial.

Guangxin Xia, Kexu Yang, Shan Jing, 2021, Clinical therapeutics.

Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.

Jingshan Shen, Jianfeng Li, Guangxin Xia, 2005, Bioorganic & medicinal chemistry letters.

Synthesis and Evaluation of PDE5 Inhibitory Activity of Novel Pyrido[2′,1′:5,1]pyrazolo[4,3‐d]pyrimidin‐4‐one Derivatives

Guanghui Tian, Jingshan Shen, Ya-bing Wei, 2007 .

A New Triterpenoid from Teucrium viscidum

Yonghui Zhang, Guangmin Yao, Xincai Hao, 2013, Molecules.

Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.

Jianxin Yu, Jing Zhang, Guangxin Xia, 2016, Bioorganic & medicinal chemistry.

A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.

Wei Huang, Wenteng Chen, Jing-kang Shen, 2014, Journal of medicinal chemistry.

Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11β-hydroxysteroid dehydrogenase type 1

Mengzhu Xue, B. Xiong, Jing-kang Shen, 2012, Molecular and Cellular Endocrinology.

SPH3643: A novel cyclin‐dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood‐brain barrier permeability

X. Liao, Guangxin Xia, Xin Li, 2020, Cancer science.

Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.

Jianxin Yu, Jing Zhang, Guangxin Xia, 2017, European journal of medicinal chemistry.

Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor.

Jingkang Shen, K. Takedomi, Yoichi Takahashi, 2022, Journal of medicinal chemistry.

Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.

K. Takedomi, Yoichi Takahashi, A. Kashima, 2022, ACS medicinal chemistry letters.

The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor

Xiaoyan Chen, Zhi-wei Gao, Guangxin Xia, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.

Yechun Xu, Lele Zhao, Z. Miao, 2015, Journal of medicinal chemistry.

Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment.

Qian Wang, Hai Qian, Di Li, 2022, Journal of medicinal chemistry.